Thrombin Generation in Patients with Atrial Fibrillation Undergoing Percutaneous Coronary Intervention

Area of Science:

• Cardiology
• Pharmacology
• Hematology

Background:

• Optimal antithrombotic treatment for atrial fibrillation (AF) patients undergoing percutaneous coronary intervention (PCI) remains debated.
• Dual therapy (clopidogrel and direct oral anticoagulant [DOAC]) is safer than triple therapy, but its efficacy is uncertain.
• This study evaluates thrombin generation (TG) to compare dual and triple antithrombotic strategies.

Purpose of the Study:

• To assess thrombin generation (TG) in patients with atrial fibrillation (AF) undergoing percutaneous coronary intervention (PCI).
• To compare TG levels under dual therapy (clopidogrel and DOAC) versus triple therapy (warfarin, aspirin, and clopidogrel).

Main Methods:

• A prospective, noninterventional trial involving patients with AF undergoing PCI.
• Patients initially received 4 weeks of triple therapy, followed by aspirin withdrawal.
• Thrombin generation was measured in platelet-rich and platelet-poor plasma at baseline, 4 weeks, and 2 weeks post-aspirin withdrawal.

Main Results:

• Thrombin generation (measured as endogenous thrombin potential [ETP]) was significantly higher immediately after PCI compared to 4 weeks later.
• These findings were consistent in both platelet-rich and platelet-poor plasma.
• ETP levels remained similar before and after aspirin withdrawal, indicating sustained TG in most patients on dual therapy.

Conclusions:

• Thrombin generation is elevated post-PCI and diminishes after 4 weeks of triple therapy.
• Aspirin withdrawal did not significantly alter TG in most patients, suggesting dual therapy may provide comparable antithrombotic effects to triple therapy after one month.
• Further research is needed to clarify the long-term efficacy of dual therapy in this patient population.